{"id":1202245,"date":"2026-07-30T00:56:27","date_gmt":"2026-07-30T00:56:27","guid":{"rendered":"https:\/\/www.europesays.com\/de\/1202245\/"},"modified":"2026-07-30T00:56:27","modified_gmt":"2026-07-30T00:56:27","slug":"wichtiger-erfolg-in-europa-neue-eu-entscheidung-staerkt-abbvies-milliardenpotenzial-wallstreetonline","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/de\/1202245\/","title":{"rendered":"Wichtiger Erfolg in Europa: Neue EU-Entscheidung st\u00e4rkt AbbVies Milliardenpotenzial | wallstreetONLINE"},"content":{"rendered":"<p>\n                            Mehr anzeigen\n                        <\/p>\n<p>Melden Sie sich <a href=\"https:\/\/www.wallstreet-online.de\/newsletter\" target=\"_blank\" rel=\"nofollow noopener\">HIER f\u00fcr den Newsletter der wallstreetONLINE Redaktion an<\/a> &#8211; alle Top-Themen der B\u00f6rsenwoche im \u00dcberblick! Verpassen Sie kein wichtiges Anleger-Thema!&#13;\n<\/p>\n<p>&#13;<br \/>\nF\u00fcr Beitr\u00e4ge auf diesem journalistischen Channel ist die Chefredaktion der wallstreetONLINE Redaktion verantwortlich.<\/p>\n<p>Die Fachjournalisten der wallstreetONLINE Redaktion berichten hier mit ihren Kolleginnen und Kollegen aus den Partnerredaktionen exklusiv, fundiert, ausgewogen sowie unabh\u00e4ngig f\u00fcr den Anleger.<\/p>\n<p>Die Zentralredaktion recherchiert intensiv, um Anlegern der Kategorie Selbstentscheider relevante Informationen f\u00fcr ihre Anlageentscheidungen liefern zu k\u00f6nnen.<\/p>\n<p>NEU: Podcast &#8222;B\u00f6rse, Baby!&#8220;<\/p>\n<p>\n                            Mehr anzeigen\n                        <\/p>\n","protected":false},"excerpt":{"rendered":"Mehr anzeigen Melden Sie sich HIER f\u00fcr den Newsletter der wallstreetONLINE Redaktion an &#8211; alle Top-Themen der B\u00f6rsenwoche&hellip;\n","protected":false},"author":2,"featured_media":1202246,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[3933],"tags":[92029,331,332,250705,548,244974,663,158,3934,3935,13,14,15,250703,12,250704],"class_list":["post-1202245","post","type-post","status-publish","format-standard","has-post-thumbnail","category-eu","tag-abbvie","tag-aktuelle-nachrichten","tag-aktuelle-news","tag-alopecia-areata","tag-eu","tag-eu-zulassung","tag-europa","tag-europaeische-union","tag-europe","tag-european-union","tag-headlines","tag-nachrichten","tag-news","tag-rinvoq","tag-schlagzeilen","tag-upadacitinib"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@de\/117006210624844419","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/1202245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/comments?post=1202245"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/1202245\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media\/1202246"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media?parent=1202245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/categories?post=1202245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/tags?post=1202245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}